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doi:10.1Objective: Higher altitudes are associated with chronic hypoxia and elevated pulmonary vascular resistance,
both potentially detrimental to patients requiring heart transplantation. The purpose of the present study was
to determine whether altitude negatively affects survival among patients undergoing heart transplantation.
Methods: The United Network of Organ Sharing database for adult patients undergoing heart transplantation from
1990 to 2008 (n¼ 36,529)was analyzed, and each patient was assigned an altitude according to their homeZIP code.
Survival was compared between patients at less than 2000 ft, 2000 or more to less than 4000 ft, and 4000 ft or more.
Adjusted survival was calculated using Cox proportional hazards analysis with propensity-matched stratification.
Results: Patients living at above 2000 ft had a 16% reduction in the risk of death at 1 year after transplant
(P ¼ .006) compared with those at lower altitudes. At 5 and 10 years, the risk reduction was 6% (P ¼ .21)
and 6% (P ¼ .114), respectively. Among patients living above 4000 ft, the 1-, 5-, and 10-year reduction in
the risk of death was 20% (P¼ .022), 12% (P¼ .057), and 15% (P¼ .0052) compared with those living below
2000 ft, respectively. Patients at high altitude had a lower incidence of diabetes, used tobacco less often, and
accounted for the greatest proportion of status 2 heart transplants. Comparing the factors predicting survival
at high and low altitudes, patients with a status 1A listing had improved outcomes at higher altitudes.
Conclusions: Patients living above 2000 ft have improved survival after heart transplantation, an advantage even
more pronounced at 4000 ft. Although the mechanism of protection remains unclear, the findings might reflect
differences in pre-2006 organ allocation. (J Thorac Cardiovasc Surg 2012;143:735-41)Supplemental material is available online.A number of epidemiologic studies have suggested that
patients with cardiovascular disease who live at higher alti-
tudes have improved survival compared with patients living
at lower elevations.1-4 Multiple factors determine whether
a high altitude exerts harm or benefit to cardiovascular
health. Environmental factors such as duration (acute,
chronic, or intermittent exposure), perinatal exposure, and
the absolute level of altitude each play a role.5 Individual
comorbidities and habits, such as tobacco abuse and exer-
cise, interact with the environmental factors to determine
the host response to altitude.
Physiologically, altitude is associated with an increased
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Xflow,6-8 which might provide a beneficial cardioadaptive
effect. In contrast, a high altitude is also associated with
increased sympathetic activity, hypocarbia, chronic
hypoxic pulmonary vasoconstriction, right ventricular
hypertrophy, and both systemic and pulmonary
hypertension.9-11 These latter attributes intuitively seem
harmful to patients with advanced heart failure and, in
particular, patients requiring heart transplantation.
Although several case reports have reported heart trans-
plant patients traveling to high altitudes and successfully ex-
ercising,12-14 these anecdotes do not address the issue related
to heart transplantation in patients living at elevation.
Pulmonary artery hypertension is a well-documented con-
traindication to heart transplantation because the donor right
ventricle that is acutely asked to pump against a high-
resistance vascular bed will fail. The outcomes in patients
with right ventricular failure after heart transplantation are
dismal.15-17 Thus, the purpose of the present study was to
determine the influence of altitude on survival after heart
transplantation. Although patients with coronary artery
disease might fare well living at higher elevations, we
hypothesized that the detrimental effects of altitude on the
pulmonary vasculature would negatively affect patients
undergoing heart transplantation and result in reduced
short- and long-term survival.TMETHODS
The United Network of Organ Sharing (UNOS) patient database (Stan-
dard Transplant Analysis and Research) was analyzed. The data filerdiovascular Surgery c Volume 143, Number 3 735
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Xcontained no identifying patient data nor transplant center identifiers. Adult
patients (18 years old) undergoing orthotopic heart transplantation in the
United States from 1990 to 2008 were included. Pre-1990 patient data were
not used, given themodern advances in immunosuppressive and prophylac-
tic regimens. Patients undergoing combined or redo transplantation were
excluded. Using a commercially available ZIP code database (www.
zipcodeworld.com), each patient in the UNOS databasewas assigned an al-
titude according to their home ZIP code.
The patients were stratified into 3 groups according to their home alti-
tude: less than 2000 ft, 2000 ft or more to less than 4000 ft, and 4000 ft
or higher. The strata were selected to assess the effect of ‘‘moderate’’
and ‘‘extreme’’ altitude in the context of the U.S. geography. Relative to
worldwide elevations, all our patients would be considered to live at
a ‘‘moderate’’ altitude.
The baseline demographic and clinical data were recorded. A compar-
ison of the baseline patient characteristics was performed using analysis of
variance for continuous variables and chi-square contingency table analysis
for dichotomous variables. The primary end point was all-cause mortality.
Post-transplant survival was compared between those living above and be-
low 2000 ft. To assess the effect of ‘‘extreme’’ altitude, additional compar-
ison was made between the patients living below 2000 ft and those living
above 4000 ft. Although we described the patient cohort in the intermediate
group (2000–4000 ft), we focused our analysis on the 4000-ft or higher
group to compare 2 highly contrasting populations. Cox proportional haz-
ards analysis with propensity-matched stratification was used to construct
survival models to determine whether altitude was an independent predic-
tor of survival. Survival models were adjusted for age, gender, body mass
index, listing status (status 1A/B vs status 2), wait list time, the presence of
a left ventricular assist device (LVAD), mean pulmonary artery pressures,
ischemic time, antigen matching, panel reactive antibody, diabetes, and ox-
ygen consumption. The incidence of acute rejection was unable to be reli-
ably determined owing to the marked variations in reporting and the
numerous missing values in the database.
Hazard ratios from the Cox proportional hazards models identified the
factors predicting survival. These factors were compared between the
high and low altitude strata using an independent samples t test. In that
analysis, a survival factor (eg, age) that explained death could potentially
have been significant within each group but was only considered signif-
icant if the magnitude of the effect between groups differed significantly.
A second Cox proportional hazards model without propensity-matched
stratification was also constructed, and the survival factors from that anal-
ysis are included online (Tables E1 and E2). The proportional hazards as-
sumption was tested using time interaction covariates. No significant
deviation from proportional hazards was observed for either altitude
comparison.
Significance was set to reflect a 95% confidence interval for all analy-
ses. Statistical analysis was performed using SAS, version 9.2 (SAS Insti-
tute, Chicago, Ill).RESULTS
A total of 36,259 patients were included in the present
study. The preoperative patient characteristics among the
3 altitude strata are listed in Table 1. As expected, the vast
majority of patients lived below 2000 ft. No differences
were found with respect to gender or the proportion of736 The Journal of Thoracic and Cardiovascular Surgpatients receiving mechanical support with a left ventricular
assist device. More patients at lower altitudes had diabetes,
used tobacco, and were listed and waited with greater ur-
gency status. In contrast, the patients at altitude and, in par-
ticular, those living at about 4000 ft, more often had 2, had
greater oxygen consumption, and had fewer comorbidities.
Compared with the lower elevation groups, the higher ele-
vation group appeared to be more sensitized. Perhaps, unex-
pectedly, the mean pulmonary artery pressures in those at
altitude were actually lower than in those at a lower
elevation.
Figure 1 depicts the survival curves for patients living
above and below 2000 ft at 1, 5, and 10 years after trans-
plantation. Both groups shared the initial perioperative de-
crease in survival. However, the curves began to diverge
within 30 days of transplant. Because 2000 ft is a relatively
low bar for altitude, we also studied patients who were at
even higher elevations. Figure 2 depicts survival curves
for patients living below 2000 ft and those living above
4000 ft at 1, 5, and 10 years after transplantation. The sur-
vival benefit of altitude was similarly observed in this ex-
treme group, both early after surgery and sustained long
term.
To quantify the observed benefit of the higher elevations,
propensity-matched survival models were used to test
whether altitude was an independent predictor of survival,
and adjusted hazard ratios were calculated for each group
(Figure 3). Patients living above 2000 ft had a 16% reduc-
tion in the risk of death at 1 year after transplant (P¼ .006).
A trend, albeit not significant, was seen for a sustained ben-
efit at 5 (6% reduction, P ¼ .21) and 10 (6% reduction,
P¼ .114) years after transplantation. Among patients living
above 4000 ft, a significant risk reduction was observed.
Compared with patients living at below 2000 ft, patients liv-
ing above 4000 ft had a 20% (P ¼ .022 ), 12% (P ¼ .057),
and 15% (P¼ .0052) risk reduction achieved at 1, 5, and 10
years after transplantation.
To identify the factors that contributed to the increased
survival in the high elevation group, the hazard ratios ob-
tained from the Cox proportional hazards models with
propensity-matched stratification were compared between
the high and low groups. Multiple factors were identified
that predicted death within either the high or low altitude
group at nearly every point. For example, elevated pulmo-
nary artery pressures, ischemic time, and HLA mismatch
all predictably contributed to mortality within each stratum.
However, when comparing these factors between strata, few
factors were significantly different (Tables 2 and 3).
Comparing patients living above and below 2000 ft,
diabetes was associated with improved survival among
patients living at a higher elevation at 5 and 10 years
(Table 2). This effect did not persist when comparing pa-
tients above 4000 ft. Longer wait times, male gender, and
lower maximal exercise oxygen consumption wereery c March 2012
TABLE 1. Baseline characteristics of patients undergoing heart transplantation
Characteristic <2000 ft 2000–4000 ft >4000 ft P value
Patients (n) 34,236 (94) 1229 (3) 1079 (3)
Age (y) 51  12 52  11 50  13 <.001
Male (%) 76.4 76.9 78.9 .18
Body mass index (kg/m2) 24.5  7.7 25  7 23.9  7.4 .0017
Diabetes (%) 16.2 15.3 10.9 <.001
Cigarette use (%) 13.3 11.9 8.9 <.0001
VO2 Max (mL/min/kg) 1.9  4.5 2.1  4.8 2.6  5.2 <.0001
LVAD at listing (%) 2.5 2 2.5 .52
Status 1A (n) 7578 (22) 207 (16.8) 140 (13) <.0001
Status 1B (n) 7450 (22) 258 (21) 198 (18.3) <.02
Status 2 (n) 19,228 (56) 773 (62.8) 744 (68.7) <.0001
Status 1A duration (days) 6.9  20 4.1  11.7 3.7  13 <.0001
Status 2 duration (days) 127.8  248 142  274 133  227 .117
Mean PAP (mm Hg) 22  17 22  17 19.9  16 .0002
HLA mismatch level 3.8  2 3.9  1.9 4  1.7 <.0001
Most recent PRA (%) 2.4  10.8 2.5  11.3 3.18  12.9 .0753
Ischemic time (h) 2.8  1.2 3  1.3 2.9  1.3 <.0001
Data in parentheses are percentages. LVAD, Left ventricular assist device; VO2 Max, maximal exercise oxygen consumption; PAP, pulmonary artery pressure; HLA, human leu-
kocyte antigen; PRA, panel of reactive antibodies.
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Xassociated with worse survival for patients above 2000 ft,
with an inconsistent effect over time. The only 2 factors
contributing to survival among patients living above 4000
ft were a designation of status 1A and the duration of status
1A (Table 3). For these patients, a status 1A designation was
associated with improved survival. Similar to the analysis of
patients living above and below 2000 ft, longer 1A times
were associated with worse survival, and although the effect
was observed at 5 and 10 years, the effect was only a 1%
difference.
DISCUSSION
The principle finding in the present study was improved
survival among heart transplant patients who live at higher
altitudes. The benefit appeared to begin at 2000 ft and was
even more marked in patients living above 4000 ft. These
observations contradict our initial hypothesis. We postu-
lated that heart transplant patients living at a higher altitude
would be particularly susceptible to the increased cardiac
workload incurred by altitude-induced hypoxia and pulmo-
nary vasoconstriction, a sequence that would ultimately re-
sult in poorer survival. Although the presence of pulmonary
hypertension negatively influenced survival within each el-
evation strata, the pulmonary artery pressures were actually
the same or slightly lower in the higher altitude group, and
pulmonary artery pressure was not a significant factor when
comparing survival characteristics between the high and
low elevation groups. As such, pulmonary hypertension
likely does not account for all our results.
A cursory view of the descriptive characteristics between
our groups would suggest that the low altitude cohort were
more ill (eg, more patients with diabetes, those who
smoked, and patients with status IA) and, thus, predictablyThe Journal of Thoracic and Cadid worse. Our survival models, however, were propensity
matched and designed to account for differences at baseline,
grouping similar acuity patients and then testing whether al-
titude could explain differences.18 Our propensity-matched
analysis demonstrated altitude to be an independent predic-
tor of survival. With the baseline characteristics accounted
for in our survival model, it is more difficult to assert that
differences in the baseline characteristics truly accounted
for our findings. We further extended our analysis to iden-
tify survival factors with hazard ratios that were signifi-
cantly different at high and low altitude. We observed that
a given factor could paradoxically exert a beneficial influ-
ence at 1 altitude strata and harm at the other. For example,
diabetes was associated with improved survival at 5 and 10
years after transplantation among patients above 2000 ft but
was associated with worsened survival below 2000 ft. Per-
haps the most unifying theme of this secondary analysis was
the observation that status 1A patients were associated with
improved survival above 4000 ft. Future studies might focus
on this subset of patients to identify what features of the sta-
tus 1A patients contributed to improved survival. One could
speculate that this group of patients included stable patients
with a LVAD who underwent transplantation during their
‘‘free’’ 30 day period of 1A time, rather than the traditional
1A patient. Although no significant relationship relative to
LVAD use at listing was found using our propensity-
matched analysis comparing survival factors at high and
low altitudes, the Cox models without propensity matching
demonstrated consistent improvement in survival among
the patients with a LVAD (Tables E1 and E2). Although
the designation of status 1A markedly improved the out-
comes in the higher altitude group, the wait times on the
status 1A list had the opposite effect. Longer wait timesrdiovascular Surgery c Volume 143, Number 3 737
FIGURE 1. Survival at 1, 5, and 10 years for adult heart transplantations
performed from 1990 to 2008, stratified by the patient’s home altitude, less
than 2000 ft versus 2000 ft or more.
FIGURE 2. Survival at 1, 5, and 10 years for adult heart transplantations
performed from 1990 to 2008, stratified by patient’s home altitude, less
than 2000 ft versus 4000 ft or more.
FIGURE 3. Horizontal error bar chart summarizing hazard ratios from the
propensity matched Cox proportional hazard analysis.
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Xfor status 1A patients living above 4000 ft were associated
with greater risk than for their counterparts living below
2000 ft. This last observation once again raises the impor-
tance of propensity-matched analysis. At baseline, patients
above 4000 ft had significantly shorter wait times than their
counterparts below 2000 ft; however, their risk of death (at 5
and 10 years) was greater as the wait times lengthened. This
observation was the most consistent across time and altitude
strata, although we concede that the increased risk was low.
Tables 2 and 3 summarize the survival factors that were
significantly different among the high and low altitude
groups. The factors that are not listed, and therefore were
not significant, were notable. Cigarette use, pulmonary
artery pressures, and panel of reactive antibodies were all
significantly different at baseline. However, after738 The Journal of Thoracic and Cardiovascular Surgery c March 2012
TABLE 2. Comparison of significant survival factors<2000 ft versus 2000 ft
Parameter
Hazard ratio
P value* Interval after transplantation (y)High altitude (>2000 ft) Low altitude (<2000 ft)
Benefit
Duration of status 1A (d) 0.99 1.001 .01 10
Diabetes 0.85 1.194 .02 5
0.9 1.22 .02 10
Risk
Duration of status 1A (d) 1.011 1.001 .043 1
Male 1.1 0.86 .04 5
VO2 Max 1.03 0.96 .02 10
VO2 Max, Maximal exercise oxygen consumption. *Independent sample t test<2000 versus>2000 ft.
Wozniak et al Cardiothoracic Transplantationcompletion of the propensity-matched analysis, they were
not found to explain the differences in survival.
In interpreting these results, the period of the data set
must be considered. This cohort of patients treated from
1990 to 2008 does not reflect the significant changes that oc-
curred with the change in heart organ allocation that oc-
curred in 2006.19 This policy was initiated to reduce death
on the waiting list by expanding regional organ sharing to
allow heart allocation to the sickest recipients within the re-
gion. We and others have reported that these changes have
resulted in a greater proportion of status 1A transplantation,
longer wait times, and longer ischemic times, without
a change in mortality.20 Before 2006, if no status I recipients
were available, the organs were next prioritized within
a given organ procurement organization to local status 2 pa-
tients. The older system probably favored transplantation of
more status 2 patients at centers above 2000 ft simply be-
cause the pool of eligible status 1 patients was small relative
to the more populated centers below 2000 ft. The present
study encompassed only 2 years of the new allocation sys-
tem, and we presume that the effect of the allocation
changes will be better seen over a longer period.
Although our analysis has identified factors that might
aid in explaining our findings, the analysis still seems to
lack a unifying explanation. This might be related toTABLE 3. Comparison of significant survival factors for<2000 versus
4000 ft
Parameter
Hazard ratio
P
value*
Interval after
transplantation (y)
High
(>4000 ft)
Low
(<2000 ft)
Benefit
Status 1A
0.42 1.089 .007 5
0.47 1.06 .009 10
Risk
Duration of
status 1A (d)
1.012 1.001 .03 5
1.011 1.001 .06 10
*Independent sample t test.
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number of factors can be accurately accounted or measured.
One factor obviously missing from our analysis is related to
acute rejection. However, within the existing data set, it was
not possible to obtain an accurate incidence of acute rejec-
tion. Too many values were missing, and the rate of report-
ing varied tremendously during study period, making the
data unreliable.
Another factor that might be very important in explain-
ing our findings is the altitude of the donor heart. Before
2006, organ allocation favored local recipients. As such,
increased survival might have been a result of an already
entrained right ventricle in a heart that originated and
was transplanted at altitude. The limits of the UNOS
data set prevented us from accurately assigning donor
heart altitude. The donor state is available, but these
data are confounded by the wide variations of altitudes
among several Western states (eg, California, Oregon,
and Washington).
The previous work in heart transplantation and altitude
has been case studies demonstrating the relative safety of
transplant patients performing exercise at altitude.12-14 In
contrast, the interest on the effect of altitude on patients
with coronary artery disease has been fairly significant.
The experience gained from these population-based studies
helps to put our findings in context. In an early study in New
Mexico, the mortality from coronary artery disease was
lower as the patient’s home altitude increased.3 The benefit
appeared to begin at 5000 ft and preferentially advantaged
male, but not female, patients. In our series, gender did
not appear to play a role from the regression analysis.
With any observational study examining the effects of al-
titude, one must consider issues related to migration.Within
the UNOS data set, we cannot determine whether patients
underwent transplantation at a high altitude center and sub-
sequently moved to a lower elevation or the reverse. In the
study by Mortimer and colleagues,3 they followed up their
patients for several years and found that traveling to lower
altitude was infrequent. A more contemporary study of pa-
tients with coronary artery disease in Switzerland also ad-
dressed migration.2 They demonstrated a reduction inrdiovascular Surgery c Volume 143, Number 3 739
Cardiothoracic Transplantation Wozniak et al
T
Xmortality in patients living at high altitude. The investiga-
tors then tracked migration over the patients’ lifetime and
identified durable protective effects in patients born at
high altitude who later moved to a lower altitude. Again,
this beneficial effect was more pronounced for the male pa-
tients than for the female patients, and they attributed this
difference to increased exercise in their male patients. The
investigators offered several nontraditional factors that
could have influenced their observation, including in-
creased ultraviolet exposure/vitamin D use and improved
cardiovascular-protective nutrients from food products
raised at altitude.
Another population-based study from Greece comparing
coronary deaths between sea-level and mountain (3100 ft)
inhabitants found similar reductions in cardiac-related
death among residents at altitude.1 Again, the effect was
more pronounced for the male patients. The present study
controlled for traditional cardiac risk factors (ie, lipids,
hypertension, diabetes) and found that despite the lower
incidence of cardiac deaths, residents at altitude had
a greater incidence of cardiac risk factors than those at sea
level. Similarly, the improvements in survival were theo-
rized to result from increased exercise among mountain
dwellers.
Admittedly, defining the mechanism behind our observed
survival improvement is challenging. Although patients at
higher altitude appeared to be less sick than those at lower
altitudes, we cannot claim that these differences were re-
lated, as the previously cited studies did, to simply lifestyle
(eg, more frequent exercise). Was our original hypothesis
falsely derived? The intention of the studies on altitude
and coronary disease was not to identify an underlying
physiologic explanation of exposure to moderate altitude.
Significant physiologic changes (ie, pulmonary hyperten-
sion, right ventricular hypertrophy) are not thought to occur
until around 9800 ft (3000 meters).21 Quite possibly, signif-
icant and independently associated restriction of the pulmo-
nary vascular bed does not occur until altitudes well above
any of those in the continental United States.
Alternatively, the well-described effects of high altitude
on pulmonary hypertension might be balanced by its salu-
brious physiologic effects. For example, exposure to
a high altitude has been shown to be associated with im-
proved functional recovery from ischemic insult, a reduction
in infarct size after ischemia, oxygen transport, mitochon-
drial biogenesis, and the efficiency of energy produc-
tion.5,22 Coronary blood flow and angiogenesis are also
thought to improve as a result of exposure to a high
altitude, although 1 study found that patients with
coronary artery disease living at moderate altitude lose
the ability to augment coronary flow.23 Right ventricular
function is enhanced in response to pulmonary hyperten-
sion, although this adaptation can become maladaptive in
the context of chronic mountain sickness and subacute740 The Journal of Thoracic and Cardiovascular Surgmountain sickness when the pulmonary vascular bed be-
comes hyper-reactive.24
In conclusion, and contrary to our initial hypothesis, pa-
tients living above 2000 ft have improved survival after
heart transplantation. The survival advantage is even more
significant for patients living above 4000 ft. These observa-
tions should allay some of the fears patients and physicians
living at higher elevations might have when considering
their candidacy for heart transplantation. Although the pa-
tients at higher altitude had a lower incidence of tobacco
use and diabetes, these factors did not explain the differ-
ences in survival between the groups. Status 1A patients liv-
ing above 4000 ft were associated with improved survival.
Although the reasons for this are uncertain, this could po-
tentially aid in explaining our findings. It remains unclear
whether other unidentified factors might play a heretofore
unrecognized role in predicting survival. The altitude of
the donor heart could be an important factor. Future studies
are needed to account for the relatively recent change in or-
gan allocation policy to standardize the degree of urgency
among patients at any altitude.References
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TABLE E1. Cox regression analysis comparing survival factors<2000 ft versus 2000 ft
Variable
1 y 5 years 10 years
<2000 ft >2000 ft
<2000 vs
>2000 ft <2000 ft >2000 ft
<2000 vs
>2000 ft <2000 ft >2000 ft
<2000 vs
>2000 ft
HR
P
value HR
P
value
P
value* HR
P
value HR
P
value
P
value* HR
P
value HR
P
value
P
value*
Age 1.01 <.0001 1.01 .04 .41 1.00 .63 1.01 .16 .21 1.00 <.0001 1.01 <.01 .07
Male 0.89 <.001 1.01 .96 .45 0.86 <.0001 1.07 .56 .08 0.89 <.0001 1.00 1.00 .24
BMI 1.00 .75 1.00 .97 .99 1.00 .73 1.00 .71 .75 1.00 .73 1.00 .41 .38
Status 1A 1.11 .02 1.05 .83 .80 1.03 .42 0.94 .71 .60 1.01 .84 0.94 .72 .70
Duration of
status 1A
1.00 .57 1.01 .03 .35 1.00 .10 1.01 .07 .13 1.00 .10 1.01 .17 .28
Diabetes 1.12 .01 0.75 .18 .07 1.18 <.0001 0.86 .29 .04 1.21 <.0001 0.92 .49 .03
LVAD at listing 1.17 .11 0.35 .15 .10 1.10 .25 0.32 .06 .04 1.12 .19 0.33 .06 .04
Mean PAP 1.01 <.0001 1.02 .03 .42 1.01 <.0001 1.01 .06 .64 1.00 <.001 1.01 .04 .26
HLA mismatch 1.06 <.0001 1.11 .09 .50 1.06 <.0001 1.11 .01 .24 1.04 <.0001 1.09 .01 .18
PRA 1.01 <.0001 1.01 .01 .55 1.00 <.0001 1.01 .02 .41 1.00 <.0001 1.01 .02 .33
Ischemic time 1.20 <.0001 1.12 .05 .27 1.13 <.0001 1.11 .01 .66 1.10 <.0001 1.07 .03 .58
VO2 Max 0.95 <.0001 0.93 .11 .74 0.96 <.0001 1.02 .63 0.11 0.96 <.0001 1.02 .49 .05
Tobacco use 0.72 <.0001 0.70 .27 .93 0.82 <.001 1.13 .59 .18 0.81 <.0001 1.12 .59 .14
BMI, Body mass index; LVAD, left ventricular assist device; PAP, pulmonary artery pressure; HLA, human leukocyte antigen; PRA, panel of reactive antibodies; VO2 Max,max-
imal exercise oxygen consumption. *Independent sample t test comparing magnitude of effect between<2000 vs>2000 ft.
TABLE E2. Cox regression comparing survival factors<2000 vs 4000 ft
Variable
1 y 5 y 10 y
<2000 ft >4000 ft
<2000 vs
>4000 ft <2000 ft >4000 ft
<2000 vs
>4000 ft <2000 ft >4000 ft
<2000 vs
>4000 ft
HR
P
value HR
P
value
P
value* HR
P
value HR
P
value
P
value* HR
P
value HR
P
value
P
value*
Age 1.01 <.0001 1.03 .01 .05 1.00 .63 1.01 .03 .04 1.00 <.0001 1.01 .02 .10
Male 0.89 <.001 0.78 .33 .62 0.86 <.0001 0.85 .36 .91 0.89 <.0001 0.83 .22 .66
BMI 1.00 .75 1.00 .82 .84 1.00 .73 1.00 .72 .73 1.00 .73 1.00 .42 .38
Status 1A 1.11 .02 0.51 .09 .06 1.03 .42 0.43 .01 .01 1.01 .84 0.53 .02 .03
Duration of
status 1A
1.00 .57 1.01 .02 .04 1.00 .10 1.01 .01 .02 1.00 .10 1.01 .01 .02
Diabetes 1.12 .01 1.03 .93 .80 1.18 <.0001 1.11 .64 .79 1.21 <.0001 1.11 .62 .65
LVAD at listing 1.17 .11 0.29 .23 .19 1.10 .25 0.19 .10 .09 1.12 .19 0.19 .11 .09
Mean PAP 1.01 <.0001 1.03 .01 .08 1.01 <.0001 1.01 .08 .38 1.00 <.001 1.01 .66 .17
HLA mismatch 1.06 <.0001 1.08 .35 .80 1.06 <.0001 1.08 .23 .75 1.04 <.0001 1.07 .18 .57
PRA 1.01 <.0001 1.01 .21 .98 1.00 <.0001 1.01 .25 .86 1.00 <.0001 1.01 .13 .58
Ischemic time 1.20 <.0001 1.35 .02 .21 1.13 <.0001 1.26 .01 .09 1.10 <.0001 1.18 .01 .20
VO2 Max 0.95 <.0001 1.00 .95 .46 0.96 <.0001 1.05 .31 .08 0.96 <.0001 1.05 .37 .08
Tobacco use 0.72 <.0001 0.68 .45 .91 0.82 <.001 1.41 .36 .16 0.81 <.0001 1.27 .49 .21
BMI, Body mass index; LVAD, left ventricular assist device; PAP, pulmonary artery pressure; HLA, human leukocyte antigen; PRA, panel of reactive antibodies; VO2 Max,max-
imal exercise oxygen consumption. *Independent sample t test comparing magnitude of effect between<2000 vs>4000 ft.
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